The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
OLUMIANT (Eli Lilly Australia Pty Ltd)
Product name
OLUMIANT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
232 (255 working days)
Active ingredients
baricitinib
Registration type
EOI
Indication
Alopecia Areata
OLUMIANT is indicated for the treatment of severe alopecia areata (AA) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 Pharmacodynamic properties; Clinical trials).